Zobrazeno 1 - 10
of 10 540
pro vyhledávání: '"TKI"'
Publikováno v:
JAAD Case Reports, Vol 53, Iss , Pp 177-180 (2024)
Externí odkaz:
https://doaj.org/article/3bdf49728854495c90df78b04466e38f
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Introduction The majority of metastatic renal cell carcinoma (mRCC) patients receive one or more VEGFR TKI agents, alone or in combination with an immune-oncology (IO) agent or an mTOR inhibitor. To date, the cost of adverse events (AEs) com
Externí odkaz:
https://doaj.org/article/8ef7bbd24a304d5b9b93e0aceb84d027
Autor:
Ji-Youn Han, Myung-Ju Ahn, Ki Hyeong Lee, Yun-Gyoo Lee, Dong-Wan Kim, Young Joo Min, Sang-We Kim, Eun Kyung Cho, Joo-Hang Kim, Gyeong-Won Lee, Sung Sook Lee, Na Mi Lee, Hyun Woo Jang, Heewon Han, Hyejoo Park, Jieon Lee, Byoung Chul Cho
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Background Lazertinib is a potent, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with significant efficacy in patients with EGFR T790M-mutated non-small cell lung cancer (NSCLC). This
Externí odkaz:
https://doaj.org/article/8bfcc4d65fa047f3a5990e84062ee6df
Autor:
Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhi Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lu, Yanping Hu, Liyan Jiang, Qiming wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wancheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Jie Weng, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Hongying Wei, Jiawei Wei, Zheyu Zhang, Qiong Wu
Publikováno v:
Cancer Communications, Vol 44, Iss 9, Pp 1005-1017 (2024)
Abstract Background The initial randomized, double‐blinded, actively controlled, phase III ANEAS study (NCT03849768) demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first‐line therapy in epidermal growth factor re
Externí odkaz:
https://doaj.org/article/2b6ae05d34ee40d883ed46122a1d5428
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 4327-4343 (2024)
Yinxue Zhou,1,* Tingyu Wu,2,* Jiaxing Sun,1 Huanhuan Bi,1 Yuting Xiao,1 Yanmei Shao,1 Weizhong Han,1 Hongmei Wang1 1Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, People’s Repub
Externí odkaz:
https://doaj.org/article/3b073d2f225445aba7d0455d7f38e9d8
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Sunitinib, a newly developed multi-targeted tyrosine kinase inhibitor (TKI), has become a common therapeutic option for managing advanced renal cell carcinoma (RCC). Examining the mechanism underlying the interaction between sunit
Externí odkaz:
https://doaj.org/article/88eb762f5aae4fe0a0f8b15f1fd87a9c
Autor:
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, Riccardo Asnaghi, Ambra Carnevale Schianca, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5121-5139 (2024)
The ever-growing knowledge regarding NSCLC molecular biology has brought innovative therapies into clinical practice; however, the treatment situation in the non-metastatic setting is rapidly evolving. Indeed, immunotherapy-based perioperative treatm
Externí odkaz:
https://doaj.org/article/3ed05c0b4ba740369ca1630364d8a082
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background The development of acquired EGFR-TKI treatment resistance is still a major clinical challenge in the treatment of non-small cell lung cancer (NSCLC). This study aimed to investigate the role of HDAC1/FOXK1/miR-33a signaling in EGF
Externí odkaz:
https://doaj.org/article/955f165724ae455f867c0f8f8221034a
Publikováno v:
Open Life Sciences, Vol 19, Iss 1, Pp 1345-56 (2024)
The aim of this study is to assess the impact of serum magnesium (Mg) levels on prognostic outcomes in patients with non-small cell lung cancer (NSCLC) undergoing treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI).
Externí odkaz:
https://doaj.org/article/5f969346d19d4b008d95b3fd0c3b7eac
Autor:
Sareen T. Ali, David J. VanderWeele
Publikováno v:
Current Oncology, Vol 31, Iss 7, Pp 4015-4021 (2024)
A 48-year-old woman without obvious environmental risk factors was diagnosed with metastatic urothelial carcinoma harboring a mutation in EGFR typical of driver mutations for non-small cell lung cancer. Within a year, her cancer progressed on four st
Externí odkaz:
https://doaj.org/article/48ce2d3b52a94770baf63023f1f06161